DiaMedica Therapeutics (NASDAQ:DMAC) vs. Conduit Pharmaceuticals (NASDAQ:CDT) Head to Head Survey

Conduit Pharmaceuticals (NASDAQ:CDT) and DiaMedica Therapeutics (NASDAQ:DMAC) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, dividends, valuation, profitability, institutional ownership, risk and analyst recommendations.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Conduit Pharmaceuticals and DiaMedica Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Conduit Pharmaceuticals	0	0	0	1	4.00
DiaMedica Therapeutics	0	0	3	0	3.00

DiaMedica Therapeutics has a consensus target price of $7.00, indicating a potential upside of 12.00%. Given DiaMedica Therapeutics’ higher probable upside, analysts plainly believe DiaMedica Therapeutics is more favorable than Conduit Pharmaceuticals.

Institutional & Insider Ownership

3.3% of Conduit Pharmaceuticals shares are owned by institutional investors. Comparatively, 10.1% of DiaMedica Therapeutics shares are owned by institutional investors. 30.9% of Conduit Pharmaceuticals shares are owned by company insiders. Comparatively, 7.2% of DiaMedica Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Conduit Pharmaceuticals and DiaMedica Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Conduit Pharmaceuticals	N/A	N/A	-328.67%
DiaMedica Therapeutics	N/A	-43.67%	-40.81%

Risk & Volatility

Conduit Pharmaceuticals has a beta of 2.18, indicating that its stock price is 118% more volatile than the S&P 500. Comparatively, DiaMedica Therapeutics has a beta of 1.46, indicating that its stock price is 46% more volatile than the S&P 500.

Valuation and Earnings

This table compares Conduit Pharmaceuticals and DiaMedica Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Conduit Pharmaceuticals	N/A	N/A	-$540,000.00	N/A	N/A
DiaMedica Therapeutics	N/A	N/A	-$19.38 million	($0.56)	-11.16

Summary

Conduit Pharmaceuticals beats DiaMedica Therapeutics on 6 of the 10 factors compared between the two stocks.

About Conduit Pharmaceuticals

Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.

About DiaMedica Therapeutics

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.